Axonics reports Q3 EPS 0c, consensus 13c
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2024
0mins
Q3 Revenue Performance: Axonics reported Q3 revenue of $116.2 million, exceeding the consensus estimate of $113.5 million, marking a 25% year-over-year growth.
Growth Drivers: The revenue increase was attributed to higher utilization from existing customers and the onboarding of new accounts for both sacral neuromodulation and Bulkamid(R).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
